Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from X4 Pharmaceuticals ( (XFOR) ).
On August 13, 2025, X4 Pharmaceuticals announced the closing of an upsized $85 million private placement, which increased from the originally planned $60 million to include an investor with pre-existing rights. The funds will support the development of mavorixafor for chronic neutropenia and the commercialization of WHIM. This private placement, led by Coastlands Capital and supported by several life science investors, was conducted without a public offering and will be followed by a registration statement with the SEC for resale of the shares.
The most recent analyst rating on (XFOR) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on X4 Pharmaceuticals stock, see the XFOR Stock Forecast page.
Spark’s Take on XFOR Stock
According to Spark, TipRanks’ AI Analyst, XFOR is a Neutral.
X4 Pharmaceuticals faces significant financial challenges, notably in profitability and cash flow, despite growth in revenue. Technical indicators suggest a downward trend, while valuation metrics indicate potential undervaluation. The earnings call and recent corporate events offer some optimism with strategic initiatives and clinical progress, but market and sales challenges remain.
To see Spark’s full report on XFOR stock, click here.
More about X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on developing and commercializing innovative therapies for rare diseases of the immune system. Leveraging expertise in CXCR4 and immune system biology, X4 has developed mavorixafor, marketed in the U.S. as XOLREMDI® for its first indication, and is conducting a global Phase 3 clinical trial for chronic neutropenic disorders. The company is headquartered in Boston, Massachusetts.
Average Trading Volume: 2,443,444
Technical Sentiment Signal: Sell
Current Market Cap: $29.43M
For detailed information about XFOR stock, go to TipRanks’ Stock Analysis page.